Last quarter (Q ), Gyre Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Gyre Therapeutics's net income was $-1.58M. See Gyre Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 96.00K	$ 794.00K	$ 7.34M	$ 20.95M	$ 0.00	$ 6.00K
Cost of Revenue	-	$ 798.00K	$ 7.38M	$ 9.16M	$ 0.00	-
Gross Profit	$ 96.00K	$ -4.00K	$ -42.00K	$ 11.79M	$ 0.00	-
Operating Expense	$ -31.55M	$ -65.79M	$ 87.85M	$ 69.16M	$ 57.28M	$ 33.83M
Operating Income	$ -48.84M	$ -65.80M	$ -87.89M	$ -57.37M	$ -57.28M	$ -33.82M
Net Non Operating Interest Income Expense	$ 4.00K	$ 537.00K	$ 39.00K	$ 561.00K	$ 2.15M	$ 2.23M
Other Income Expense	$ -4.70M	$ -57.19M	$ 39.00K	$ 568.00K	$ -46.00K	$ 1.54M
Pretax Income	$ -43.49M	$ -7.89M	$ -87.93M	$ -56.24M	$ -55.18M	$ -30.05M
Tax Provision	$ 364.00K	$ 348.00K	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -44.24M	$ -8.24M	$ -87.93M	$ -56.24M	$ -55.18M	$ -30.05M
Basic EPS	$ -1.84	$ -0.26	-	$ -2.93	$ -4.60	$ -2.68
Diluted EPS	$ -1.38	$ -0.26	$ -0.75	$ -2.93	$ -4.60	$ -2.68
Basic Average Shares	$ 145.08M	$ 31.55M	$ 116.53M	$ 19.18M	$ 12.00M	$ 11.21M
Diluted Average Shares	$ 145.31M	$ 31.55M	$ 116.53M	$ 19.18M	$ 12.00M	$ 11.21M
Dividend Per Share	$ -0.95	$ 0.24	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ -31.55M	$ 10.20M	$ 95.23M	$ 78.32M	$ 57.28M	$ 33.83M
Net Income From Continuing And Discontinued Operation	$ -44.24M	$ -8.24M	$ -87.93M	$ -56.24M	$ -55.18M	$ -30.05M
Normalized Income	$ -3.20M	$ -62.41M	-	$ -56.24M	$ -55.18M	$ -29.94M
Interest Expense	-	-	-	-	-	-
EBIT	$ -43.50M	$ -7.89M	$ -87.93M	$ -57.37M	$ -57.28M	$ -33.82M
EBITDA	$ -43.48M	$ -7.66M	$ -87.64M	$ -57.23M	$ -57.13M	$ -33.67M

Currency in USD

Gyre Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing